Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Fig. 2

Cumulative incidence of a MACE + UA, b MACE, c CV death, d MI, e stroke, f UA and g hospitalisation for heart failure (Kaplan–Meier estimates). Data presented for the overall population. CV cardiovascular, DAPA dapagliflozin, MACE major adverse cardiovascular events (CV death, MI and stroke), MI myocardial infarction, UA unstable angina

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840